JDRF, which funds Type 1 diabetes research and led a campaign calling on health insurers to expand choices for in-network Type 1 diabetes therapies, said the policy change was a “direct result of the T1D community’s advocacy.”
In February 2019, UnitedHealthcare expanded an existing agreement with Medtronic that denoted the devicemaker’s insulin pumps preferred products for children with Type 1 diabetes. The move, which UnitedHealthcare said considered the quality and cost of the devices, effectively limited in-network options for the insulin pump from three to two.
UnitedHealthcare will now cover Tandem Diabetes insulin pumps as in-network.
More articles on payers:
Walmart to launch Medicare insurance agency
Payer execs: 5 ways COVID-19 will affect business
14 health plan deals this year
At the Becker's 5th Annual Fall Payer Issues Roundtable, taking place November 2–3 in Chicago, payer executives and healthcare leaders will come together to discuss value-based care, regulatory changes, cost management strategies and innovations shaping the future of payer-provider collaboration. Apply for complimentary registration now.
